Back to results
US 9,752,125 B2Granted
Differentiation of human embryonic stem cells
AssigneeJanssen Biotech, Inc.
InventorJean Xu
Life of this patent
Estimating the term…
Abstract
The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein greater than 50% of the cells in the population co-express PDX1 and NKX6.1.
Claims24
A cell culture comprising:
- a medium supplemented with ALK5 inhibitor II and a protein kinase C activator;
- human definitive endoderm cells;
- and
- a population of human cells expressing markers characteristic of the pancreatic endoderm lineage,
- wherein the presence of ALK5 inhibitor II and the protein kinase C activator in the culture increases the percentage of pancreatic endoderm cells that co-express PDX1 and NKX6.1, and results in a culture wherein greater than 60% of the cells in the population are pancreatic endoderm cells co-expressing PDX1 and NKX6.1,
- wherein the human definitive endoderm cells are derived from established lines of human pluripotent cells, and
- wherein cells in the isolated PDX1 and NKX6.1 co-expressing population express CDX2.
4 more elements
A cell culture comprising:
- a medium supplemented with ALK5 inhibitor II and a protein kinase C activator;
- human definitive endoderm cells;
- and
- a population of human cells expressing markers characteristic of the pancreatic endoderm lineage,
- wherein the presence of ALK5 inhibitor II and the protein kinase C activator in the culture increases the percentage of pancreatic endoderm cells that co-express PDX1 and NKX6.1, and results in a culture wherein greater than 60% of the cells in the population are pancreatic endoderm cells co-expressing PDX1 and NKX6.1,
- wherein the human definitive endoderm cells are derived from established lines of human pluripotent cells, and
- wherein the PDX1 and NKX6.1 co-expressing cells in the isolated population differentiate into insulin secreting cells in vivo.
4 more elements
A cell culture comprising:
- a medium supplemented with ALK5 inhibitor II and a protein kinase C activator;
- human definitive endoderm cells;
- and
- a population comprising pancreatic endoderm cells,
- wherein the presence of ALK5 inhibitor II and the protein kinase C activator in the culture increases the percentage of pancreatic endoderm cells that co-express PDX1 and NKX6.1, and results in a culture wherein greater than 90% of the cells in the population are pancreatic endoderm cells co-expressing PDX1 and NKX6.1, and
- wherein the human definitive endoderm cells are derived from established lines of human pluripotent cells.
3 more elements
A cell culture comprising:
- a medium supplemented with (2S, 5S)-(E, E)-8-(5-(4-(Trifluoromethyl)phenyl)-2,4-pentadiemoylamino) benzolactam (TPB);
- human definitive endoderm cells;
- and
- a population of human cells expressing markers characteristic of the pancreatic endoderm lineage,
- wherein the presence of TPB in the culture increases the percentage of pancreatic endoderm cells that co-express PDX1 and NKX6.1, and results in a culture wherein greater than 60% of the cells in the population are pancreatic endoderm cells co-expressing PDX1 and NKX6.1,
- wherein the human definitive endoderm cells are derived from established lines of human pluripotent cells, and
- wherein cells in the isolated population express CDX2.
4 more elements
Dependencies are inferred from the claim text.